Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a genomic diagnostics company with a diversified portfolio of tests for various types of cancer. Their latest test, TrueMRD, has demonstrated strong results in detecting cancer recurrence and has potential for a new immunotherapy monitoring indication. With planned and ongoing clinical studies and a solid financial foundation, the company has potential for double-digit growth and sustained revenue.

Bears say

Veracyte is a genomic diagnostics company that provides tests for prostate, thyroid, breast, and bladder cancer. Despite potential for upside to revenue and earnings estimates, there are several risks to Veracyte's stock, including weaker than expected sales, operating margins, and free cash flow. These risks, coupled with the company's small/mid-cap peers trading at lower EV/sales multiples, contribute to the financial analyst's negative outlook on Veracyte's stock.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.